AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon to announce agreements with the U. government to lower certain prescription drug prices, according ...
The populations of wealthy western nations are getting older and sicker, while emerging countries are demanding better ...
Danish pharma major Novo Nordisk has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide and semaglutide) injection, to be used ...
The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...
UnitedHealth Group (UNH 1.05%) and Eli Lilly (LLY +1.45%) are two of the largest and most powerful healthcare companies in ...
Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...
The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...
"Scandalous unveiling on the 'Presidential Walk of Fame' sends shockwaves through Washington. You won't believe what Trump's ...
Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.
Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...
CagriSema would be the first combo GLP-1 if it’s approved, while orforglipron would be the first GLP-1 pill approved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results